Jazz Pharmaceuticals Estimates $755M Pre-Tax Acquired IPR&D Charge From Actio Biosciences Acquisition; Expected $11.00 Negative Impact On Both GAAP And Adjusted EPS In Q3 2026

Estimated Q3 Financial Impacts Related to the Actio Biosciences, Inc. Acquisition

In connection with its acquisition of Actio Biosciences, Inc., a Delaware corporation ("Actio"), which was completed on September 15, 2026, Jazz Pharmaceuticals plc, an Irish public limited company (the "Company") currently estimates that its GAAP and non-GAAP financial results for the third quarter of 2026 will include a pre-tax charge of approximately $755 million of acquired in-process research and development ("IPR&D") expense. The expected IPR&D charge is not tax deductible and is estimated to represent an unfavorable impact of approximately $11.00 to both GAAP earnings per share ("EPS") and non-GAAP adjusted EPS for the third quarter of 2026.

The Company’s results for the quarter ended September 30, 2026, have not been finalized and are subject to the Company’s financial statement closing procedures. There can be no assurance that actual results will not differ from the preliminary estimated results described herein. In addition, the estimated unaudited financial information in this Current Report on Form 8-K (this "Report") does not present all information necessary for a complete understanding of the Company’s results for the quarter ended September 30, 2026, and should not be viewed as a substitute for the Company’s full condensed consolidated financial statements for the quarter ended September 30, 2026 prepared in accordance with GAAP.